20th May 2025 A plain language summary: MARIPOSA-2 study of amivantamab combinations for non-small-cell lung cancer
25th Apr 2025 Plain language summary of first-line treatment with amivantamab-lazertinib for high-risk EGFR-positive lung cancer from the MARIPOSA study
